__

PWRM, Power 3 Medical Products Inc., PWRM.OB

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

PWRM's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).

Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro(R)) and breast cancer (BC-SeraPro(TM)).

PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer's disease (NuroPro-AD), Parkinson's disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA.

PWRM delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii.

These presentations discussed NuroPro, PWRM's diagnostic test, and focused on PWRM's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

Alzheimer's disease is a progressive and fatal brain disease. Alzheimer's destroys brain cells, causing memory loss and problems with thinking and behavior severe enough to affect work, lifelong hobbies or social life. Alzheimer's gets worse over time, and it is fatal. Today it is the seventh-leading cause of death in the United States.

According to recent estimates, as many as 2.4 million to 4.5 million Americans have Alzheimer's disease (AD). Unless the disease can be effectively treated or prevented, the number of people with AD will increase significantly if current population trends continue. That's because the risk of AD increases with age, and the U.S. population is aging. The number of people age 65 and older is expected to grow from 39 million in 2008 to 72 million in 2030, and the number of people with AD doubles for every 5-year interval beyond age 65.

Early and careful evaluation is important because many conditions can cause dementia, some of which are treatable or reversible. Potentially reversible conditions include depression, adverse drug reactions, metabolic changes, and nutritional deficiencies. The earlier an accurate diagnosis of Alzheimer's disease is made, the greater the gain in managing symptoms and allowing the person to take part in planning for their future.

Furthermore, PWRM has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc., a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy.

PWRM plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into PWRM, with PWRM remaining as the surviving company in the merger.

The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

More about PWRM at www.power3medical.com

**************************************************************

According to reports, Transocean Ltd. (NYSE: RIG) and subsidiary Triton Asset Leasing GmbH are being sued over oil spill by the state of Louisiana

**************************************************************

According to reports, The Travelers Companies, Inc. (NYSE: TRV) spent $720,000 in the second quarter to lobby the federal government on insurance reform and other issues

**************************************************************

TRC Companies, Inc. (NYSE:TRR) reported that it has been awarded a $1.2 million contract by the New York Power Authority (NYPA) for engineering services during decommissioning of a generating unit at the Charles Poletti Power Project in Astoria, NY.

The Power Authority ceased operations at the more than three-decade-old plant in January 2010. Under a 2002 agreement, The Power Authority committed to construct a state-of-the-art clean-generating unit at the same site in Astoria, which became operational in December 2005.

Under the contract, TRR will provide design, engineering, planning and construction management services, including pre-demolition site investigation; design of construction documents for the future demolition project; recommendations to effectively implement the work; and recommendations of action for existing plant auxiliary buildings that are no longer required.

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Each advertising commitment has now expired.